Related Experiment Video
Updated: May 14, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Trophic factor gene therapy for Parkinson's disease
Jeffrey H Kordower1, Anders Bjorklund
1Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA. jkordowe@rush.edu
Summary
Gene therapy using trophic factors shows promise for Parkinson's disease (PD) treatment, offering potential structural and functional recovery in preclinical models and early clinical trials.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder with no cure.
- Current pharmacological treatments manage motor symptoms but are not curative and can cause side effects.
- Gene delivery of trophic factors like GDNF and neurturin is an emerging therapeutic strategy.
Purpose of the Study:
- To review the current state of gene delivery research for Parkinson's disease using trophic factors.
- To assess the efficacy of trophic factor gene therapy in preclinical models and clinical trials.
Main Methods:
- Review of preclinical studies in rodent and nonhuman primate models of PD.
- Analysis of outcomes from open-label and double-blinded clinical trials of trophic factor gene delivery.
Main Results:
- Gene delivery of GDNF and neurturin demonstrated structural and functional recovery in PD models.
- Positive results observed in open-label clinical trials, though double-blinded data is pending.
- Trophic factors offer a potential disease-modifying approach for Parkinson's.
Conclusions:
- Trophic factor gene delivery represents a promising therapeutic avenue for Parkinson's disease.
- Further investigation, particularly through rigorous clinical trials, is needed to confirm efficacy and safety.
More Related Videos
08:09Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
08:33Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
Published on: February 28, 2016
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...